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Pleuroparenchymal ﬁbroelastosis in patients
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What should the rheumatologist do?
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Abstract
Pleuroparenchymal ﬁbroelastosis (PPFE) is a rare new interstitial lung disease (ILD) characterized by the ﬁbrotic thickening of the
visceral pleura and subadjacent parenchymal areas of the upper lobes This study reveals that patients with ILD-SSc associated with
chest HRCT evidence of PPFE require close and recurrent follow-up with periodic evaluation of lung function parameters, DLCO and
chest HRCT. Rheumatologists should be aware of this new radiological ﬁnding which is accompanied by a negative prognosis,
especially when associated with a progressive course. Patients with this radiological pattern need to be monitored with particular
attention.
Abbreviations: DLCO = diffuse capacity for carbon monoxide, FEV1 = forced expiratory volume in 1 second, FVC = forced vital
capacity, HRTC = high resolution computed tomography, HP = hypersensitivity pneumonitis, ILD = interstitial lung diseases, LFT =
lung function tests, NSIP = non-speciﬁc interstitial pneumonia, PPFE = pleuroparenchymal ﬁbroelastosis, TLC = total lung capacity,
UIP = usual interstitial pneumonia.
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1. Introduction
Pleuroparenchymal ﬁbroelastosis (PPFE) is a rare new interstitial
lung disease (ILD) characterized by the ﬁbrotic thickening of the
visceral pleura and subadjacent parenchymal areas of the upper
lobes.[1–3]Histological features of PPFE includeaggregates of elastic
ﬁbers, especially in subpleural areas, and intra-alveolar collagenous
ﬁbrosis with septal elastosis (with orwithout collagen thickening of
the visceral pleura).[3–5] First described 25 years ago,[6] PPFE is now
considered a distinct entity that may be familial, idiopathic, or
associated with pathological conditions such as hypersensitivity
pneumonitis (HP), pneumoconiosis, bone marrow or lung
transplant, drug-induced lung toxicity, and connective tissue
diseases.[6–12] PPFE may coexist with different radiological and
histological ILD patterns: usual interstitial pneumonia (UIP), non-
speciﬁc interstitial pneumonia (NSIP), granulomatous lungdiseases,
and chronic hypersensitivity pneumonitis (HP).[13] Radiological
PPFE has also been reported in patients with recurrent respiratory
infections, which is in line with the theory that repeated
inﬂammatory stimuli may trigger the disease.[14] A high prevalence
of PPFE-like lesions was recently detected by chest high resolution
computed tomography (CT) in a cohort of patientswith ILDrelated
to connective tissue disorders.[15] This type of alteration was
associated with a negative prognosis.[15]
Here we analyzed a cohort of 11 patients with PPFE associated
with systemic sclerosis (SSc) in order to explore the clinical and
radiological characteristics of this disease. Patients with PPFE
associated with systemic sclerosis (2 men and 9 women, mean age
66.6±15.8 years) were diagnosed according to international
guidelines at Siena Referral Centre for ILD and Lung Transplant,
Siena Rheumatology Unit and Careggi Referral Centre for
Systemic Sclerosis. All patients had a radiological diagnosis of
PPFE and a deﬁnite diagnosis of systemic sclerosis, as well as an
observation period of almost 24 months. The clinical and
functional details were analyzed retrospectively in relation to
demographic data, smoking, occupational/environmental, and
exposure history. The following parameters had been recorded:
age, sex, bronchoalveolar lavage (BAL) differential cell count, lung
function tests, and blood gas analysis parameters. Lung function
test parameters had been measured according to ATS/ERS
guidelines to obtain percentages of predicted forced expiratory
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volume in1second (FEV1), forced vital capacity (FVC), and diffuse
capacity for carbon monoxide (DLCO) values.[2] The study had
been approved by the local ethics committee. Bronchoscopy with
BAL collection had been performed in 9/11 patients for diagnostic
purposes at the same time as blood gas analysis and lung function
tests (LFT), after written informed consent. BAL samples had been
obtained by instillation of 4 aliquots of 50mL saline solution by
ﬁberoptic bronchoscope. The aliquots had been immediately
aspirated. The ﬁrst BAL sample had been kept separate from the
others andwas not used for immunological tests. Sub-samples had
been cultured formicrobes, fungi, andviruses to exclude infections.
Cells had been separated by centrifuge and the ﬂuid fraction frozen
for enzyme assays. Differential cell counts had been done. All
patients underwent chest x-ray in postero-anterior and lateral
projections and chest high resolution CT of the chest (HRCT) at
full inspiration at the time of ILD diagnosis. All CT scans were
reviewed retrospectively by experienced radiologists for PPFE-like
lesions (i.e., apical subpleural dense consolidations associated or
not associated with pleural thickening). SSc patients with PPFE
were identiﬁedon the basisofHRCTevidenceof PPFE radiological
features.
1.1. Demographic, clinical, and immunological features
The clinical and demographic features of our population are
summarized in Table 1. All patients were Caucasian and showed
diffuse systemic sclerosis. The patients showed increased serum
C-reactive protein levels (ranging from 6.9 to 1mg/L); 6/11
patients showed speckled antinuclear antibody pattern with anti-
Scl-70 positivity and 3/11 patients showed anti-U1-RNP anti-
bodies. A single patient was asymptomatic at the ﬁrst visit. The
most common respiratory symptom was dyspnoea (Table 1); 1
patient showed spontaneous pneumothorax at onset and another
developed pneumomediastinum 2 years after diagnosis. Most
patients had bibasal crackles (Table 1). Blood gas analysis on
room air revealed mild hypoxia (paO2 70.1±9.3mmHg and
paCO2 34.8±5.5mmHg).
1.2. Radiological features
Chest HRCT revealed a radiological pattern of NSIP in 2 patients
while the others a usual interstitial pneumonia (UIP) pattern, with
lower-lobe-predominant peripheral and bibasal reticulations,
traction bronchiectasis and honeycombing, and no ground-glass
attenuations. The extent of emphysema in all patients was limited
to a small percentage of parenchyma and was associated with
smoking history. In all patients, PPFE radiological features showed
upper-lobe-predominant focal pleural and subpleural thickenings
and bilateral apical dense consolidations (Figs. 1 and 2). In a
Table 1
The clinical and functional characteristics of patients with systemic
sclerosis associated with pleuroparenchymal ﬁbroelastosis.
No. of patients 11
Male (%) 2/11 (18)
Age (mean±SD) 66.6±15.8
Smoke (n=8): former:current:never 1:2:5
Onset symptoms:
• Dyspnoea 6/8
• Cough 1/8
• Pnx 1/10
• Crackles 6/8
• Clubbing 3/6
Pulmonary function tests onset
FEV1% 80.6±18
FVC% 80.1±19.5
DLCO% 58.4±30
Pulmonary function tests follow up
FEV1% 59.5±15.1
FVC% 60.9±20.3
DLCO% 38.4±18.7
DLCO=diffuse capacity for carbon monoxide, FEV1= forced expiratory volume in 1 second, FVC=
forced vital capacity.
Figure 1. (A–F) PPFE (A–C) in an 80-year-old womanwith scleroderma involving the upper lobes and the apical segments of the inferior lobes including the ﬁssures.
Three years after the diagnosis (D–F) it is dear a mid increase of ﬁbrosis, especially on the right side (arrows in B, C, E, F). The esophagus is dilated with food
stagnation (arrowhead in D) due to the scleroderma involvement. PPFE=pleuroparenchymal ﬁbroelastosis.
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patient with advanced disease, the architectural distortion also
involved adjacent and lower lobes (Fig. 2). At 12 to 18 months
follow-up, chest HRCTwas unchanged in 3/11 patients, 1 patient
had undergone lung transplant due to rapid deterioration of the
clinical condition and the others showed progressive worsening
and evolution of radiological alterations with progressive
involvement of the middle and lower lobes.
1.3. Functional results
Lung function parameters in this population were collected at
onset of the disease and at 12month follow-up: FEV1%was 80.6
±18 and FVC% 80.1±19.5. DLCO%was depressed: 58.4±30.
At 2-year follow-up, patients had restrictive functional deﬁcit and
decreased diffusion capacity for carbon monoxide (DLCO)
(Fig. 3A–C).
Figure 2. (A, B) PPFE in a 59-year-old woman with scleroderma and allergic asthma. Coronal-oblique (A) and sagittal (B) multiplanar reconstructions show the
predominant involvement of the upper lobe and apical segment of the lower lobe on the right side. Note the involvement of the major ﬁssure (arrow in B) that is
atypical ﬁnding in PPFE. PPFE=pleuroparenchymal ﬁbroelastosis.
Figure 3. FVC (%), FEV1 (%), and DLCO (%) predicted values in patients at the time of diagnosis and after 2 years of follow-up (∗P< .05). DLCO=diffuse capacity
for carbon monoxide, FEV1= forced expiratory volume in 1second, FVC= forced vital capacity.
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1.4. Bronchoalveolar lavage ﬁndings
BAL features revealed elevated BAL neutrophil and eosinophil
percentages due to inﬂammatory interstitial lung involvement.
BAL cell percentages were: macrophages 73.4±50.2, lympho-
cytes 20.1±17.8, neutrophils 4.4±2.9, and eosinophils 3.8±3.
Figure 4 shows BAL cell populations, slight increase in
polymorphonuclear cells and inﬂammatory foamy macrophages
(about 5%). Figure 4 reports BAL cellular populations in a
patient with PPFE associated with systemic sclerosis.
In conclusion, this retrospective study indicates the clinical
importance of radiological evidence of PPFE in a cohort of
patients with ILD-SSc. Radiological PPFE-like lesions were
associated with increased risk of pneumothorax and pneumo-
mediastinum, rapid lung function decline and poor prognosis.
Most radiological alterations involved the upper lobes and were
readily detected.
This is an important clinical ﬁnding worthy of further
investigation: patients with ILD-SSc associated with chest HRCT
evidence of PPFE require close and recurrent follow-up with
periodic evaluation of lung function parameters, DLCO and
chest HRCT. Rheumatologists should be aware of this new
radiological ﬁnding which is accompanied by a negative
prognosis, especially when associated with a progressive course.
Patients with this radiological pattern need to be monitored with
particular attention.
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Figure 4. Bronchoalveolar lavage cellular populations from a patient affected
by PPFE and systemic sclerosis. PPFE=pleuroparenchymal ﬁbroelastosis.
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